drugset / Trial / NCT06388083
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
Timeline
- Start
- 2024-07-31
- Primary completion
- 2028-02
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tinlarebant | Small molecule | 5 mg | Oral |